<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03727711</url>
  </required_header>
  <id_info>
    <org_study_id>GN15UR229</org_study_id>
    <nct_id>NCT03727711</nct_id>
  </id_info>
  <brief_title>TPTNS: Home vs Hospital Treatment for Overactive Bladder</brief_title>
  <official_title>&quot;Transcutaneous Tibial Nerve Stimulation as a Conservative Treatment for Overactive Bladder Dysfunction -A Randomised Controlled Trial Comparing Home Versus Hospital Based Treatment&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NHS Greater Glasgow and Clyde</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Glasgow</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Glasgow Caledonian University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NHS Greater Glasgow and Clyde</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of home versus hospital Transcutaneous Posterior Tibial Nerve Stimulation (TPTNS).&#xD;
      TPTNS has been shown to be an effective treatment of overactive bladder in hospital. We aim&#xD;
      to see if this effect is replicated at home.&#xD;
&#xD;
      80 patients will be recruited, 40 into each arm.&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
        1. Women aged ≥18 years&#xD;
&#xD;
        2. Clinical diagnosis of Overactive Bladder (OAB)&#xD;
&#xD;
        3. Post-void residual urine volume of &lt; 100ml&#xD;
&#xD;
        4. Able to do questionnaires&#xD;
&#xD;
        5. Able to consent and willing to participate&#xD;
&#xD;
      Exclusion Criteria&#xD;
&#xD;
        1. Cardiac pacemaker in situ&#xD;
&#xD;
        2. Leg ulcer/skin condition affecting both lower legs&#xD;
&#xD;
        3. Diagnosed peripheral vascular disease&#xD;
&#xD;
        4. Absent sensation at the electrode site&#xD;
&#xD;
        5. Current Urinary Tract Infection (UTI) - must be treated with appropriate antibiotics as&#xD;
           per the unit protocol prior to commencing study&#xD;
&#xD;
        6. Pregnancy&#xD;
&#xD;
        7. Previous Percutaneous Tibial Nerve Stimulation (PTNS) /Sacral Nerve Stimulation (SNS)&#xD;
           course&#xD;
&#xD;
        8. Previous intravesical botox treatment&#xD;
&#xD;
        9. Unable to complete questionnaires&#xD;
&#xD;
      TPTNS will be taught to the home group and delivered to the participants in the hospital&#xD;
      group in individual appointments: 12 treatment sessions of 30 minutes duration, delivered&#xD;
      twice weekly over a 6 week period. Two surface electrodes are applied to the right ankle.&#xD;
      These electrodes are attached to an electrical stimulator, programmed to safely deliver&#xD;
      electric pulses.&#xD;
&#xD;
      On completion of 6 sessions, all participants will be contacted and asked to do a Patient&#xD;
      Global Impression of Improvement Scale (PGIIS) and Patient Perception of Bladder Condition&#xD;
      (PPBC). After 12 sessions (the final treatment session) all participants will be reviewed by&#xD;
      the investigators in the hospital and the outcome measures repeated. Participants receiving&#xD;
      home treatment will be posted out a 3 day bladder diary to complete. At this point the&#xD;
      participants receiving home treatment will return the machine. All participants will complete&#xD;
      and return a 72-hour bladder diary and validated questionnaires routinely used at the study&#xD;
      centre to measure lower urinary tract symptoms - The International Consultation of&#xD;
      Incontinence Modular Questionnaire - Female Lower Urinary Tract Symptoms (ICIQ-FLUTS) long&#xD;
      form, the International Consultation of Incontinence Modular Questionnaire - Urinary&#xD;
      Incontinence questionnaire (ICIQ-UI short-form. The Hospital Anxiety and Depression Scale&#xD;
      (HADS) and the European Quality of Life - 5D Questionnaire (EQ-5D) will also be measured.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">September 3, 2018</start_date>
  <completion_date type="Anticipated">August 4, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 3, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the International Consultation of Incontinence Modular - Female Lower Urinary Tract Symptoms (ICIQ-FLUTS) Long Form Questionnaire total score</measure>
    <time_frame>At 6 weeks (i.e. after the last TPTNS treatment) and at 12 weeks (i.e. 6 weeks after last the TPTNS treatment)</time_frame>
    <description>The ICIQ-FLUTS Long Form is a patient-completed questionnaire for evaluating female lower urinary tract symptoms and impact on quality of life (QoL) - 18 questionnaire items are asked and summed to calculate total score. Total score range (0-69) - a higher score indicates a worse outcome. Bother scales are not incorporated in the overall score but indicate impact of individual symptoms for the patient .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in number of urgency incontinence episodes recorded on 72 hour bladder diary.</measure>
    <time_frame>At 6 weeks (i.e. after the last TPTNS treatment) and at 12 weeks (i.e. 6 weeks after last the TPTNS treatment)</time_frame>
    <description>Patient Perception of Intensity of Urgency Severity (PPIUS) Scores on the bladder diary are recorded when a participant experiences incontinence (range 0-4): 0 indicates no urgency, 1-4 indicate urgency experienced (at increasing severity). Number of episodes of urge incontinence are identified and summed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in individual urgency score on International Consultation of Incontinence Modular Questionnaire - Female Lower Urinary Tract Symptoms (ICIQ-FLUTS) Long Form Questionnaire</measure>
    <time_frame>At 6 weeks (i.e. after the last TPTNS treatment) and at 12 weeks (i.e. 6 weeks after last the TPTNS treatment)</time_frame>
    <description>Change in numerical scores for Urgency. Scoring range on questionnaire (0-4) - a higher number indicates a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in individual frequency score on International Consultation of Incontinence Modular Questionnaire - Female Lower Urinary Tract Symptoms (ICIQ - FLUTS) Long Form Questionnaire</measure>
    <time_frame>At 6 weeks (i.e. after the last TPTNS treatment) and at 12 weeks (i.e. 6 weeks after last the TPTNS treatment)</time_frame>
    <description>Change in numerical score on the questionnaire. Scoring range on questionnaire (0-4) - a higher number indicates a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in individual nocturia score on International Consultation of Incontinence Modular Questionnaire - Female Lower Urinary Tract Symptoms (ICIQ - FLUTS) Long Form Questionnaire</measure>
    <time_frame>At 6 weeks (i.e. after the last TPTNS treatment) and at 12 weeks (i.e. 6 weeks after last the TPTNS treatment)</time_frame>
    <description>Change in numerical score on the questionnaire. Scoring range on questionnaire (0-4) - a higher number indicates a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in incontinence symptom severity</measure>
    <time_frame>At 6 weeks (i.e. after the last TPTNS treatment) and at 12 weeks (i.e. 6 weeks after last the TPTNS treatment)</time_frame>
    <description>Change in International Consultation of Incontinence Modular Questionnaire - Urinary Incontinence short-form (ICIQ-UI SF) numerical scores. Scoring range (0-21) - 4 subscales summed for overall score on questionnaire; a higher score indicates increased severity. Self-diagnostic item un-scored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean urgency perception scores recorded on 72 hour bladder diary •</measure>
    <time_frame>At 6 weeks (i.e. after the last TPTNS treatment) and at 12 weeks (i.e. 6 weeks after last the TPTNS treatment)</time_frame>
    <description>Change in Patient Perception of Intensity of Urgency Severity (PPIUS) Scores on the bladder diary. Range for PPIUS (0-4); a higher score indicates increased severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PGIS (Patient Global Impression of Improvement Scale) Score</measure>
    <time_frame>At 6 weeks (i.e. after the last TPTNS treatment) and at 12 weeks (i.e. 6 weeks after last the TPTNS treatment)</time_frame>
    <description>Change in numerical score on the questionnaire. Range (1-7); higher scores indicate least improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HADS (Hospital Anxiety and Depression) scores</measure>
    <time_frame>At 6 weeks (i.e. after the last TPTNS treatment) and at 12 weeks (i.e. 6 weeks after last the TPTNS treatment)</time_frame>
    <description>The HADS is a 14 item scale that generates ordinal data. Seven of the items relate to anxiety and seven relate to depression. Individual item score range (0-3) which are summed for total score. Total score range (0-21) for either Anxiety or Depression. Higher scores indicate a worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Overactive Bladder</condition>
  <condition>Detrusor, Overactive</condition>
  <arm_group>
    <arm_group_label>Home Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be taught home treatment with TPTNS - twice weekly, 30 minute sessions for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hospital Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive hospital treatment with TPTNS - twice weekly, 30 minute sessions for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TPTNS</intervention_name>
    <description>We will be comparing hospital treatment to TPTNS at home</description>
    <arm_group_label>Home Treatment</arm_group_label>
    <arm_group_label>Hospital Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Women aged greater than or equal to 18 years&#xD;
&#xD;
             2. Clinical diagnosis of OAB&#xD;
&#xD;
             3. Post-void residual urine volume of &lt; 100ml&#xD;
&#xD;
             4. Able to do questionnaires&#xD;
&#xD;
             5. Able to consent and willing to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Cardiac pacemaker in situ&#xD;
&#xD;
             2. Leg ulcer/skin condition affecting both lower legs&#xD;
&#xD;
             3. Diagnosed peripheral vascular disease&#xD;
&#xD;
             4. Absent sensation at the electrode site&#xD;
&#xD;
             5. Current UTI - must be treated with appropriate antibiotics as per the unit protocol&#xD;
             prior to commencing study&#xD;
&#xD;
             6. Pregnancy&#xD;
&#xD;
             7. Previous PTNS /SNS&#xD;
&#xD;
             8. Previous intravesical botox treatment&#xD;
&#xD;
             9. Unable to complete questionnaires&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ciara M Daly, MB Bch BAO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Elizabeth University Hospital Glasgow</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maureen Travers</last_name>
    <phone>0141 232 1813</phone>
    <email>Maureen.Travers@ggc.scot.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Queen Elizabeth University Hospital</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ciara Daly, MB Bch BAO</last_name>
      <phone>0141 201 1100</phone>
      <email>ciara.daly@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>August 11, 2017</study_first_submitted>
  <study_first_submitted_qc>October 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2018</study_first_posted>
  <last_update_submitted>October 30, 2018</last_update_submitted>
  <last_update_submitted_qc>October 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>transcutaneous posterior tibial nerve stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

